dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Carles Galceran, Joan |
dc.contributor.author | Pichler, Angelika |
dc.contributor.author | Korunkova, Hana |
dc.contributor.author | Tomova, Antoaneta |
dc.contributor.author | Ghosn, Marwan |
dc.contributor.author | El Karak, Fadi |
dc.date.accessioned | 2021-03-11T14:42:37Z |
dc.date.available | 2021-03-11T14:42:37Z |
dc.date.copyright | 2018 |
dc.date.issued | 2019-03-01 |
dc.identifier.citation | Carles J, Pichler A, Korunkova H, Tomova A, Ghosn M, El Karak F, et al. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU Int. 2019 Mar 1;123(3):456–64. |
dc.identifier.issn | 1464-410X |
dc.identifier.uri | https://hdl.handle.net/11351/5753 |
dc.description | Càncer de pròstata resistent a la castració metastàsica; Cabazitaxel; Qualitat de vida relacionada amb la salut |
dc.description.sponsorship | Research and analysis was supported by Sanofi. The authors were responsible for all content and editorial decisions, and received no honoraria for development of this manuscript. Editorial support was provided by Amber Wood and Anna Longjaloux of MediTech Media, funded by Sanofi. The authors would also like to thank Teri Michelini of Sanofi for support in preparing this manuscript. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | BJU International;123(3) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | Drug Therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/bju.14509 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.14509 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.event.productor | Biblioteca |
dc.contributor.authoraffiliation | [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pichler A] Department of Hematology and Oncology, Landeskrankenhaus Hochsteiermark, Leoben, Austria. [Korunkova H] Department of Oncology and Radiotherapy, University Hospital, Plzen, Czech Republic. [Tomova A] Department of Oncology, Complex Oncology Center, Plovdiv, Bulgaria. [Ghosn M, El Karak F] Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon |
dc.identifier.pmid | 30098093 |
dc.identifier.wos | 000460173100017 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |